For decades, the lupus community has faced a difficult reality: targeted treatment options are limited, with only two biologics approved in the U.S. to treat one of the most common forms of the condition, systemic lupus erythematosus (SLE).1 For the 5 million people globally living with this highly heterogeneous set of autoimmune diseases, the variability in their experiences – from ambiguity of symptoms to therapy response – lead to delays in diagnosis and care.2 Their challenges extend...
